… Treatment with once-daily eslicarbazepine acetate 800 mg and 1200 mg was more effective
than placebo and generally well tolerated in patients with partial-onset seizures refractory to …

… • Across the phase III trials,[22,24,25] the relative reductions from baseline in seizure
frequency with eslicarbazepine acetate 800 or 1200 mg once daily ranged from 33% to 45% …

… in 2009 for adjunctive treatment in adult subjects of partial-onset seizures, with or without …
recent studies on eslicarbazepine acetate in the treatment of drug-resistant partial epilepsy. …

OBJECTIVE: To evaluate the long-term safety, tolerability and efficacy of once-daily eslicarbazepine
acetate (ESL) as adjunctive therapy in adults with partial-onset seizures. METHODS…

… onset seizures and was found to be efficacious and well tolerated. Monotherapy studies in
adult epileptic patients and add-on studies in epileptic … III studies in adult epileptic patients are …

… Purpose: To evaluate the long-term efficacy and safety of once daily eslicarbazepine
acetate (ESL) as adjunctive therapy for partial-onset seizures in adults with epilepsy. …

… To evaluate the pharmacokinetics of eslicarbazepine acetate (ESL) at steady-state in
adults with partial-onset seizures who have taken ESL for at least 1 year with one or two …

… one of three groups: treatment with eslicarbazepine acetate once daily (QD, n … Eslicarbazepine
acetate was efficacious and well tolerated as an adjunctive therapy of refractory epileptic …

Purpose: To study the efficacy and safety of eslicarbazepine acetate (ESL) as adjunctive
therapy for refractory partial seizures in adults with ≥4 partial‐onset seizures (simple or …

… of eslicarbazepine acetate (ESL), a new voltage-gated sodium channel blocker, in epileptic
children … Similar to adults, ESL was rapidly metabolized to eslicarbazepine. In all age groups, …